This technology involves extracting protein from Chikso, a native Korean cattle breed distinguished from Hanwoo by single nucleotide polymorphisms, and hydrolyzing it with alkaline enzymes. The resulting peptide extract is fractionated using size-exclusion chromatography to produce peptides with both antihypertensive and antioxidant activities. These fractions are used in pharmaceutical compositions for preventing and treating hypertension, as well as in health functional food ingredients.
While commercial ACE inhibitors like captopril and enalapril are primary treatments for hypertension, they are associated with side effects such as cough, hypotension, headaches, and kidney damage. Furthermore, concerns regarding the safety of synthetic antioxidants have increased the demand for natural alternatives. Meanwhile, Chikso is at risk of extinction because farmers avoid raising them due to slow growth and long maturation periods, which limit profitability. Research into bioactive peptides derived from Chikso meat has been insufficient.
This technology involves hydrolyzing Chikso protein at 60°C for 2 hours, drying it at 55°C for 24 hours to obtain a peptide extract under 10kDa, and isolating highly active peptides by selecting the 5th to 8th fractions from 5mL chromatography eluates. These peptides simultaneously inhibit ACE, reducing angiotensin II production, and provide free radical scavenging effects. Applicable to blood pressure management supplements, natural antihypertensive adjuncts, and premium livestock byproducts, this technology provides food-derived, low-side-effect blood pressure regulation materials while adding new economic value to the endangered Chikso breed.
This invention was developed with support from the Rural Development Administration's project for developing value-added livestock technology from native cattle to meet diverse consumer demands.
N/A
